The 2023 European Lung Cancer Congress (ELCC 2023) published that the monotherapy of CEACAM5-targeting ADC SAR408701 (Tusamitamab Ravtansine) had showed antitumor activity and safety in patients with CEACAM5-positive non-squamous non-small cell lung cancer who have received multiple treatment regimens. This evidence concerns the gene CEACAM5 and non-small cell squamous lung carcinoma.